Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign

Wambier, Carlos Gustavo; Vañó‐Galván, Sergio; McCoy, J. Philip; Pai, Suraj; Dhurat, Rachita; Goren, Andy

doi:10.1016/j.jaad.2020.07.099

Cited by 47 publications

(79 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Additionally, a recent publication has demonstrated that COVID-19 disease severity was directly correlated with AGA progression; men with higher Hamilton-Norwood stages were more likely to experience severe disease and death. 7 Further evidence connecting COVID-19 to androgens has been reported in prostate cancer patients undergoing androgen depravation therapy (ADT).…”

Section: Introductionmentioning

confidence: 98%

WITHDRAWN: Proxalutamide (GT0918) Reduces the Rate of Hospitalization and Death in COVID-19 Male Patients: A Randomized Double-Blinded Placebo-Controlled Trial.

McCoy¹,

Goren²,

Cadegiani³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Importance: Previously, we have reported a retrospective cohort analysis demonstrating the protective effect of anti-androgens (5-alpha-reductase inhibitors) in COVID-19. Objective: To determine if the anti-androgen proxalutimide is an effective treatment for men with ambulatory mild COVID-19 disease.Design: A double-blinded, randomized, prospective, investigational study of proxalutamide for the treatment men with ambulatory mild COVID-19 disease.Setting: Outpatient centers (Brasilia, Brazil) from July 15 to December 1, 2020. Participants: Men with ambulatory mild COVID-19 disease (WHO ordinal scale ≤3).Interventions: Proxalutimide 200mg/day, or standard of care for 30 days or until full COVID-19 remission. Main Outcome and Measures: Percentage of subjects hospitalized due to COVID-19 [Time Frame: 30 days].Results: A total of 214 men were included and completed the trial; 114 men were randomized to the proxalutamide group, and 100 men were randomized to the control group. A statistically significant reduction in the percentage of subjects hospitalized due to COVID-19 was observed in men taking proxalutamide (0%) compared to the standard of care (27%), (p<0.001). The percentage of men requiring mechanical ventilation was reduced in the proxalutamide group (0%) compared to control (9%), (p<0.001). Zero fatalities occurred in the proxalutamide group, versus 2 in the control group.Conclusions and Relevance: Men with ambulatory mild COVID-19 disease (WHO ordinal scale ≤3) receiving anti-androgen treatment with proxalutamide, had significantly reduced rate of hospitalization compared to men not receiving anti-androgen treatment. Trial Registration: NCT04446429

show abstract

Section: Introductionmentioning

confidence: 98%

WITHDRAWN: Proxalutamide (GT0918) Reduces the Rate of Hospitalization and Death in COVID-19 Male Patients: A Randomized Double-Blinded Placebo-Controlled Trial.

McCoy¹,

Goren²,

Cadegiani³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…The patient weighed 79 kg had a body mass index of 26.1 kg/m 2 and did not present with acne or the 'Gabrin' sign. [1][2][3]…”

Section: Case Presentationmentioning

confidence: 99%

Expression of concern: potential risk for developing severe COVID-19 disease among anabolic steroid users

Cadegiani

Lin

Goren³

et al. 2021

BMJ Case Rep

Self Cite

View full text Add to dashboard Cite

A severe case of COVID-19 was observed in an otherwise healthy 28-year-old man who had taken oxandrolone 40 mg/day as an anabolic steroid. The patient had been taking oxandrolone for enhanced bodybuilding 30 days prior to presenting to an outpatient clinic with COVID-19 symptoms. The patient reported that his symptoms have rapidly worsened over the course of 4 days prior to presenting at the clinic. As part of an experimental antiandrogen treatment for hyperandrogenic men suffering from COVID-19, he was administered a single 600 mg dose of the novel antiandrogen proxalutamide. Twenty-four hours after administration of this dose, marked improvement of symptoms and markers of disease severity were observed. To our knowledge, this is the first case that potentially links anabolic steroid use to COVID-19 disease severity.

show abstract

“…2 Few pityriasis rosea (PR) and PR-like eruptions have been reported during COVID-19 infection. 3,4 Herein, we report a case of PR-like eruption as a leading manifestation of COVID-19.…”

Section: Funding Sourcesmentioning

confidence: 99%

5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia

McCoy¹,

Cadegiani

Wambier

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign

Cited by 47 publications

References 5 publications

WITHDRAWN: Proxalutamide (GT0918) Reduces the Rate of Hospitalization and Death in COVID-19 Male Patients: A Randomized Double-Blinded Placebo-Controlled Trial.

WITHDRAWN: Proxalutamide (GT0918) Reduces the Rate of Hospitalization and Death in COVID-19 Male Patients: A Randomized Double-Blinded Placebo-Controlled Trial.

Expression of concern: potential risk for developing severe COVID-19 disease among anabolic steroid users

5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia

Contact Info

Product

Resources

About